Биодоступность: обзор

Intravenous injection delivers the drug directly into the bloodstream, bypassing absorption barriers and metabolism, achieving 100% bioavailability. Oral drugs must traverse the gastrointestinal tract, where they undergo absorption and hepatic metabolism before reaching systemic circulation, resulting in lower bioavailability due to first-pass metabolism and other absorption factors.

First-pass metabolism occurs when drugs are metabolized by enzymes in the intestinal wall or liver before reaching systemic circulation. Drugs like lidocaine undergo extensive first-pass metabolism, significantly reducing their bioavailability and making oral administration ineffective. This process is a major determinant of whether a drug can be given orally or requires alternative administration routes.

Gastric pH influences drug solubility and absorption; weakly acidic drugs absorb better in the stomach, while weakly basic drugs absorb in the intestines. Intestinal motility alters the drug's residence time in absorption sites, either enhancing or impeding uptake. Together, these factors significantly impact the fraction of drug reaching systemic circulation.

Enzyme activity in the gut wall and liver metabolizes drugs before they reach systemic circulation, directly reducing bioavailability. Drugs with high enzyme susceptibility experience significant metabolism during this phase. Understanding enzyme activity is essential for predicting oral bioavailability and determining whether conceptual approaches overcoming bioavailability problems are needed.

Bioavailability studies evaluate the fraction of administered drug reaching systemic circulation and its absorption efficiency. These studies determine therapeutic utility, identify suitable administration routes, and optimize formulations to improve absorption and systemic delivery. Insights guide the design and approval of new and improved drug formulations, ensuring safety and efficacy.

Oral administration viability depends on enzyme activity, gastric pH, and intestinal motility. Drugs undergoing extensive first-pass metabolism, like lidocaine, cannot be given orally because insufficient drug reaches systemic circulation. Intravenous administration bypasses these barriers, making it suitable for drugs with poor oral bioavailability or when rapid systemic delivery is required.

Bioavailability determines the proportion of administered drug reaching systemic circulation in active form, directly affecting therapeutic effectiveness. It indicates whether a drug will achieve intended therapeutic outcomes at a given dose. Bioavailability assessment guides dosing decisions, formulation selection, and administration route choice, ensuring optimal drug efficacy and patient safety.